West Emily S, Alemayehu Wondu, Munoz Beatriz, Melese Muluken, Imeru Alemush, West Sheila K
Dana Center for Preventive Ophthalmology, Johns Hopkins University, Baltimore, MD 21205, USA.
Ophthalmic Epidemiol. 2005 Aug;12(4):279-86. doi: 10.1080/09286580591005769.
Trachoma is the leading infectious cause of blindness worldwide. Surgery is available to correct trichiasis, which results from repeated episodes of infection with C. trachomatis. However, trichiasis recurrence rates post-surgery are very high. Methods for reducing post-surgical trichiasis recurrence need to be explored. This paper outlines the design of the Surgery for Trichiasis, Antibiotics to prevent Recurrence (STAR) Clinical Trial currently underway in Ethiopia. The STAR trial, funded by The National Eye Institute, is a randomized, controlled clinical trial of antibiotic use at time of trichiasis surgery, comparing topical tetracycline to single-dose azithromycin for the surgical patient and single-dose azithromycin for the surgical patient and all household members. The primary outcome is trichiasis recurrence at one-year. Data from this trial will be critical in helping to determine future policy on antibiotic treatment for C. trachomatis following surgery.
沙眼是全球失明的主要感染性病因。手术可用于矫正睑内翻，睑内翻是由沙眼衣原体反复感染引起的。然而，手术后睑内翻复发率非常高。需要探索降低术后睑内翻复发的方法。本文概述了目前正在埃塞俄比亚进行的睑内翻手术联合抗生素预防复发（STAR）临床试验的设计。由美国国立眼科研究所资助的STAR试验是一项关于睑内翻手术时使用抗生素的随机对照临床试验，比较局部用四环素与单剂量阿奇霉素对手术患者的效果，以及单剂量阿奇霉素对手术患者及其所有家庭成员的效果。主要结局是一年时睑内翻复发情况。该试验的数据对于帮助确定术后沙眼衣原体抗生素治疗的未来政策至关重要。
